US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Sanofi Winthrop Industrie

< Previous 1 2 3 4 Next >
News headline image
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Online availability of Sanofi’s half-year financial report for 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi completes acquisition of Blueprint Medicines
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi announces extension of Blueprint tender offer
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Availability of the Q2 2025 Aide mémoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Sanofi successfully prices €1.5 billion bond issue
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi completes acquisition of DR-0201
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Annual General Meeting of April 30, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
From Sanofi Winthrop Industrie
Via GlobeNewswire
< Previous 1 2 3 4 Next >